Biocon Withheld Info, Amgen Says in Bone-Drug Patent Suit (1)

Amgen Inc. filed a lawsuit in Massachusetts federal court accusing Biocon Ltd. units of infringing nearly three dozen patents with its proposed biosimilars of the bone drugs Prolia and Xgeva.

Biocon’s Bmab 1000, the working name for biosimilars of both treatments, infringes 34 patents covering the drugs’ active ingredient denosumab and their formulation and manufacturing processes, according to a complaint filed Monday in the US District Court for the District of Massachusetts.

Amgen’s suit said Biocon didn’t provide it with key details about how the biosimilars are made as required under federal law, which hampered its ability to assess infringement. ...